UK real-world evidence
Select an institution to reveal findings
-
NHS Greater Glasgow
and ClydenAMDPreviously treated39 eyesPost-loading phase -
Moorfields Eye Hospital,
Bedford Hospitals
NHS TrustnAMDTreatment-naïve26 eyes12 months -
The Royal Wolverhampton
NHS TrustnAMDTreatment-naïve &
previously treated86 eyes8−9 months -
University Hospitals
Bristol and Weston NHS
Foundation TrustnAMDTreatment-naïve96 eyes12 months
-
South Tyneside and
Sunderland NHS
Foundation TrustnAMDPreviously treated45 eyes12 months -
York and Scarborough
Teaching Hospitals NHS
Foundation TrustnAMD & DMOTreatment-naïve &
previously treated249 eyes12 months -
University Hospitals of
Leicester NHS TrustnAMD & DMOPreviously treated126 eyes12 months -
Imperial College
Healthcare NHS TrustnAMD & DMOTreatment-naïve &
previously treated190 eyes12 months
Prescribing information
UK prescribing information and adverse event reporting information for EYLEA® (aflibercept) 40 mg/mL and 114.3 mg/mL solution for injection is available via the QR codes below. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.
EYLEA® (aflibercept)
40 mg/mL
EYLEA® (aflibercept)
114.3 mg/mL
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Bayer plc. If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.Further information is available on the "contact" tab at www.bayer.co.uk.
Produced and funded by Bayer.